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Background: Various antigen-specific immunoassays are available for the serological diagnosis of autoimmune
bullous diseases. However, a spectrum of different tissue-based and monovalent antigen-specific assays is required
to establish the diagnosis. BIOCHIP mosaics consisting of different antigen substrates allow polyvalent
immunofluorescence (IF) tests and provide antibody profiles in a single incubation.
Methods: Slides for indirect IF were prepared, containing BIOCHIPS with the following test substrates in each
reaction field: monkey esophagus, primate salt-split skin, antigen dots of tetrameric BP180-NC16A as well as
desmoglein 1-, desmoglein 3-, and BP230gC-expressing human HEK293 cells. This BIOCHIP mosaic was probed
using a large panel of sera from patients with pemphigus vulgaris (PV, n = 65), pemphigus foliaceus (PF, n = 50),
bullous pemphigoid (BP, n = 42), and non-inflammatory skin diseases (n = 97) as well as from healthy blood donors
(n = 100). Furthermore, to evaluate the usability in routine diagnostics, 454 consecutive sera from patients with
suspected immunobullous disorders were prospectively analyzed in parallel using a) the IF BIOCHIP mosaic and b) a
panel of single antibody assays as commonly used by specialized centers.
Results: Using the BIOCHIP mosaic, sensitivities of the desmoglein 1-, desmoglein 3-, and NC16A-specific substrates
were 90%, 98.5% and 100%, respectively. BP230 was recognized by 54% of the BP sera. Specificities ranged from
98.2% to 100% for all substrates. In the prospective study, a high agreement was found between the results
obtained by the BIOCHIP mosaic and the single test panel for the diagnosis of BP, PV, PF, and sera without serum
autoantibodies (Cohen’s κ between 0.88 and 0.97).
Conclusions: The BIOCHIP mosaic contains sensitive and specific substrates for the indirect IF diagnosis of BP, PF,
and PV. Its diagnostic accuracy is comparable with the conventional multi-step approach. The highly standardized
and practical BIOCHIP mosaic will facilitate the serological diagnosis of autoimmune blistering diseases.* Correspondence: enno.schmidt@uk-sh.de
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Autoimmune bullous disorders are characterized by
autoantibodies against desmosomal proteins (in pem-
phigus), adhesion molecules of the dermal-epidermal
junction (in pemphigoid diseases), and epidermal/ tissue
transglutaminase (in dermatitis herpetiformis), respect-
ively [1-3]. The most frequent autoimmune bullous dis-
eases are bullous pemphigoid and pemphigus, with
incidences varying considerably between geographical
regions [4-8]. Incidences for BP range from 13.4- 42 new
patients/ million inhabitants per year [5,6,8,9]. In a
population aged 80 years and above the incidence of BP
has been reported to be 150–190 new patients/million/
year [6,10]. In central Europe, pemphigus is less frequent
with incidences ranging from 0.6 to 6.8 new patients/
million/year [5,8,11], higher incidences can be found in
Southeastern Europe, the Mediterranean region, Iran
and the Jewish population [7,12]. In pemphigoid gesta-
tionis and mucous membrane pemphigoid incidences of
2.0 patients/million/year were reported [6,13]. Inci-
dences of the other entities are below 1.0/million/year.
Diagnosis relies on a combination of clinical features
as well as the detection of skin-/ mucous membrane-
bound and circulating autoantibodies [14,15]. The
diagnostic gold standard is still the visualization of
skin-/ mucous membrane-bound autoantibodies by direct
immunofluorescence (IF) microscopy [16]. Advances in
the identification of target antigens (summarized in
Table 1) and the subsequent development of an increasing
number of sensitive and specific assays for the detection
of circulating autoantibodies, including Western blotting
of cell-derived and recombinant forms of the target
antigens, immunoprecipitation, and ELISA, allow sero-
logical diagnosis in the majority of patients [15]. Several
ELISA systems using recombinant fragments of BP180,
BP230, desmoglein 1, desmoglein 3, envoplakin, and type
VII collagen have become commercially available and are
highly valuable diagnostic tools (MBL, Nagoya, Japan and
EUROIMMUN AG, Luebeck, Germany) [17-23].
Usually, the determination of serum autoantibodies
is a multi-step procedure comprising an initial screen-
ing step by indirect IF microscopy using frozen sec-
tions of one or two tissues followed by more specific
tests that aim at identifying the target antigen(s). In-
direct IF microscopy on monkey esophagus (for pem-
phigus) and human skin, where the dermal-epidermal
junction has been split by 1 M NaCl solution (for
pemphigoid diseases), has been elucidated as the most
sensitive screening tests [24-27]. The subsequent elab-
orate identification of the target antigen varies amongst
different laboratories.
Here, to facilitate the serological diagnosis of immuno-
bullous disorders, a multiplex IF BIOCHIP mosaic has
been developed that combines screening and targetantigen-specific substrates in a single miniature incuba-
tion field. Validation of the BIOCHIP showed high speci-
ficity and high sensitivity for pemphigus vulgaris (PV),
pemphigus foliaceus (PF), and bullous pemphigoid (BP).
In the second set of experiments, a large panel of
consecutive sera from suspected autoimmune blistering
disease patients sent to the Laboratory for Auto-
immune Diagnostics of the Dermatology Department
at the University of Luebeck was analysed with both




For the validation of the novel BIOCHIP mosaic, sera
from patients with BP (n = 42), PV (n = 65), and PF
(n = 50) were used. Patients were characterized by (i)
the typical clinical phenotype, (ii) positive direct IF re-
sult, and (iii) serum autoantibodies against BP180
NC16A, desmoglein (Dsg) 3, and Dsg1, respectively. In
addition, sera from patients with linear IgA dermatosis,
non-inflammatory skin diseases (NISD), including vas-
cular leg ulcers, basal cell carcinoma, and squamous cell
carcinoma (n = 97), and healthy blood donors (HBD,
n = 100), were used. All sera were anonymized before test-
ing. For the prospective comparative study, 454 consecu-
tive sera from patients with suspected autoimmune
bullous disease were analyzed independently by expe-
rienced staff members of the diagnostic laboratories of
EUROIMMUN and the dermatology department, using
both the BIOCHIP mosaic and the routine multi-step diag-
nostic algorithm. The study was approved by the local
ethic committees (10–017).
In 9 patients (PV, n = 3; PF, n = 3; BP, n = 3), sera were
analyzed during the course of the disease at 3–5 differ-
ent time points. Disease activity for skin lesions: score of
4, >10 lesions; score of 3, 4 to 10 lesions; score of 2, 1 to
3 lesions; score of 1, clinical remission on immunosup-
pressive therapy; score of 0, clinical remission without
immunosuppressive therapy) [28]. Scoring was done
retrospectively based on photographs and patient
records; serum was drawn on the same day when photo-
graphs were taken.
BIOCHIP mosaic
The membrane bound extracellular domains of Dsg1
(amino acids 1–569;) and Dsg3 (amino acids 1–640)
were cloned as described [22] with the modification of
using alternate antisense primers to include the respec-
tive coding regions for the transmembrane (TM)
domains: CAA TGT CTG CAC ATA GCT CTA GGC
GTC GAC TTA ATG ATG ATG ATG ATG AT (Dsg1)
and ATA CTC GAG TTA ATG ATG ATG ATG ATG
ATG GGT CAA CAG CAG AAG GGG GGC CAA C
Table 1 Overview of target antigens in immunobullous diseases and diagnostic methods used in this study
Disease Target antigen Routine multi-step approach1
Pemphigus vulgaris Desmoglein 3 Desmoglein 3 ELISA [22]
Pemphigus foliaceus Desmoglein 1 Desmoglein 1 ELISA [22]
Paraneoplastic pemphigus Desmoglein 3 Desmoglein 3 ELISA [22]
Envoplakin Envoplakin ELISA [21]
Periplakin/ Desmoplakin I/II Immunoblot with extract of cultured HaCaT cells [21]
Indirect IF microscopy on rat and monkey bladder
Bullous pemphigoid BP180 BP180 NC16A ELISA [20]
BP230 BP230 ELISA [51]
Soluble ectodomain of BP180 (LAD-1) BP180 4575 (c-terminal fragment) Immunoblot [33,63]
LAD-1 Immunoblot [33,63]
Pemphigoid gestationis BP180 BP180 NC16A ELISA [20]
Complement binding test
Linear IgA dermatosis Soluble ectodomain of BP180 (LAD-1) Immunoblot with conditioned medium of cultured
HaCaT cells (IgA reactivity) ) [33,63]
BP230 BP230 ELISA [51]
Lichen planus pemphigoides BP180 BP180 NC16A ELISA [51]
BP230 BP230 ELISA [51]
Mucous membrane pemphigoid Soluble ectodomain of BP180 (LAD-1) Immunoblot with conditioned medium of cultured
HaCaT cells (IgG and IgA reactivity) [33]
BP180 BP180 NC16A ELISA [20]
BP230 BP230 ELISA [51]
Laminin 332 Immunoblot with extracellular matrix of cultured HaCaT cells [13,35]
laminin γ1/anti-p200 pemphigoid p200 protein/ Laminin γ1 Immunoblot with extract of human dermis [34]
Immunoblot with recombinant laminin γ1 C-term [37]
Epidermolysis bullosa acquisita Type VII collagen Immunoblot with recombinant NC1-domain of type VII collagen [36]
Dermatitis herpetiformis Epidermal/tissue transglutaminase, gliadin Transglutaminase ELISA deamidated gliadin-analogous
fusion peptide-specific ELISA [32]
1in addition, all sera were subjected to indirect IF microscopy on human salt-split skin and monkey esophagus. The exact diagnostic algorithm applied in this
study is detailed in [38].
IF, immunofluorescence; LAD-1, linear IgA dermatosis antigen 1(soluble ectodomain of BP180); BP180NC16A, targeted extracellular domain of BP180.
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domain of BP230 (BP230gC; amino acids 1875–2649)
was amplified from an EST cDNA (DKFZp686C04183Q,
acc. no. BX475892, Imagene, Berlin, Germany) in two
separate fragments to delete an intron using primer pairs
ATA GTC GAC GCC ATG GAC TGT ACC TTC AAA
CCA GAT TTT GAG and ATA TCG TCT CTA TCT
CTA AGG GTG TCA AAA CCT TCA CC and ATA
TCG TCT CAA GAT AGC TAA GAA CAA GCA GTA
TG and ATA CTC GAG TAA GGA AGA ATA GTA
GAG GC. The two BP230gC fragments are linked to-
gether, employing the unique BspHI site. The cDNAs
were digested with the appropriate restriction enzymes
and then ligated with linearized pTriEx-1 (Merck Bios-
ciences, Darmstadt, Germany).
HEK293 cells (ATCC, CRL-1573) were cultivated and
transfected with the pTriEx-1 constructs of Dsg1-TM,
Dsg3-TM, and BP230gC as described [22] and seeded oncover slides. After cultivation for 48 hrs at 37°C, cells
were fixed with formalin (Dsg) or acetone (BP230) for
10 min and stored in liquid nitrogen until further pro-
cessing. Other cover glasses were coated with recombin-
ant tetrameric NC16A (BP180-NC16A-4X), expressed as
described previously [20], and with frozen tissue sections
of monkey esophagus and primate 1 M NaCl-split skin.
Cover glasses were automatically cut into millimeter-
sized fragments (BIOCHIPs) and glued side by side on
microscopy slides, resulting in multiparametric BIO-
CHIP mosaics (Figure 1A) for simultaneous incubation
of each serum sample on all substrates.
Slides containing the BIOCHIP mosaics were incu-
bated with serial serum dilutions (starting with 1:10 in
PBS-Tween) for 30 min at room temperature, rinsed with
a flush of PBS-Tween and immersed in PBS-Tween for
5 min. For detection of bound antibodies, fluorescein iso-
thiocyanate (FITC)-conjugated goat anti-human IgA/G
Figure 1 BIOCHIP mosaic for immunobullous disorders. (A) On a standard-sized slide, there are ten incubation fields each with six different
BIOCHIPs. (B, C) Representative stainings after incubation with a bullous pemphigoid (B) and pemphigus vulgaris (C) serum. Desmoglein (Dsg) 1,
Dsg3, and BP230gC (C-terminal globular domain of BP230) are expressed in human HEK293 cells. BP180 NC16A is directly coated on the BIOCHIP.
HEK293 cells transfected with pTriEx-1 serve as negative control.
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temperature, followed by washing as described before.
The slides were then embedded using mounting medium
(EUROIMMUN) and examined by fluorescence micros-
copy. Titer steps of 1:10, 1:32, 1:100, 1:320, 1:1000 and
1:3200 were obtained for correlation with disease activity
in selected sera.
Diagnosis of BP was made based on reactivity with
salt-split skin or monkey esophagus and reactivity with
BP180 or BP230. In case of basal membrane zone stain-
ing without reactivity against BP180 or BP230 the diag-
nosis was “pemphigoid disease”. When no reactivity was
seen in any of the six biochips of one incubation field, a
negative result was obtained.
Multi-step serum analysis
All samples were analyzed by experienced investigators
using indirect IF microscopy on monkey esophagus and
1 M NaCl-split human skin [26] for the detection of anti-
human IgG and IgA secondary antibodies (both Bio-Rad,
Munich, Germany) and a MicroImaging microscope(Carl Zeiss, Jena, Germany). In case of suspected pem-
phigoid gestationis and paraneoplastic pemphigus, IF
microscopy on salt-split human skin (complement
binding [29]) and on rat/monkey bladder was per-
formed, respectively. According to IF results and clin-
ical suspicion, target antigen-specific assays were
employed, including (i) Dsg 1-specific ELISA [22], (ii)
Dsg 3-specific ELISA [22], (iii) BP180-specific ELISA
[20,30], (iv) BP230-specific ELISA [19,31], (v)
envoplakin-specific ELISA [21], (vi) transglutaminase-
specific ELISA [32], (vii) deamidated gliadin-analogous
fusion peptides-specific ELISA [32] (all EUROIMMUN;
all performed following the manufacturer’s instructions),
(viii) immunoblotting (IB) with the soluble ectodomain
of BP180 (LAD-1) in conditioned concentrated medium
of cultured HaCaT [33], (ix) IB with dermal extract [34],
(x) IB with cultured HaCaT cells [21], (xi) IB with the
extracellular matrix of cultured HaCaT cells [35], (xii) IB
with the recombinant NC1-domian of type VII collagen
[36], and (xiii) IB with the recombinant C-terminus of
laminin γ1 [37] (Table 1). In all sera with suspected BP,
Table 2 Characteristics of pemphigoid disease-related
substrates used in the BIOCHIP mosaic
Disease BP180-NC16A-4X BP230gC





Pemphigus vulgaris 0/65 0/65
Pemphigus foliaceus 0/50 0/50
Linear IgA disease 0/18 0/18
HBD 1/100 0/100
NISD 7/97 0/97
BP230gC, c-terminal globular domain of BP230; HBD, healthy blood donors;
NISD, non-inflammatory skin diseases; 95%CI, 95% confidence intervals.
Table 3 Characteristics of pemphigus-related substrates
used in the BIOCHIP mosaic
Disease Desmoglein 1 Desmoglein 3
Pemphigus vulgaris 33/65 64/65
Sensitivity 52.3 98.5
95%CI 39.5% to 64.9% 91.7% to 100%
Specificity 100 99.6%
95%CI 98.6% to 100% 98.6% to 100%
Pemphigus foliaceus 45/50 3/50
Sensitivity % 90% not applicable
95%CI 78.2% to 96.7%
Specificity % 100% 99.6%
95%CI 98.6% to 100% 97.9% to 100%
Linear IgA disease 0/18 0/18
Bullous pemphigoid 0/42 1/42
HBD 0/100 0/100
NISD 0/97 0/97
HBD, healthy blood donors; NISD, non-inflammatory skin diseases; 95%CI, 95%
confidence intervals.
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algorithm of the autoimmune laboratory, Department of
Dermatology, University of Luebeck, applied in this
study is detailed in [38].
Diagnosis was based on (i) a positive ELISA, (ii) a
positive indirect IF in combination with a positive IB re-
sult, or (iii) positive results in 2 different IBs. A serum
was evaluated as “negative” when all tests were unreact-
ive or showed only a weak staining at a dilution of 1:10.
For post hoc analysis of sera with discordant results
compared to the BIOCHIP mosaic, additional analyses
were performed, including Dsg 1-, Dsg 3-, BP180-, and
BP230-specific ELISA (MBL) [17,19,30].
Statistics
To determine the sensitivity and specificity of the BIO-
CHIPs used in the evaluated mosaic, receiver operating
curves (ROC) were analyzed. Confidence intervals, sensi-
tivity and specificity were calculated using SigmaPlot
11.0 analysis software (SSI, San Jose, CA, USA). Cohen’s
Kappa was calculated with Gnu R open access software
(R Development Core Team 2009; R Foundation for
Statistical Computing, Vienna, Austria, volume 2.13,
package “irr”) to evaluate the inter-rate analytical agree-
ment between the BIOCHIP mosaic and the multi-step
procedure [39]. κ values of 0.41-0.60 are rated as moder-
ate concordance, κ values of 0.61-0.80 as substantial and
of 0.81-1.00 almost perfect concordance [40]. Sera were
anonymized before analysis.
Results
Validation of the BIOCHIP mosaic
Anti-basal membrane zone reactivity was seen in 41 of 42
BP sera (98.8%). Antibodies against tetrameric BP180
NC16A and BP230gC were found in 42 (100%) and 23
(54.8%) BP sera, respectively. Specificities were calculated
to be 98.8%, 98.2%, and 100% (Table 2). Staining of a rep-
resentative BP serum is shown in Figure 1B.
Intercellular epithelial staining on monkey esophagus
by indirect IF was observed in 65 PV and 49 PF sera
resulting in sensitivities of 100% and 98.0%, respectively.
Anti-Dsg3 antibodies were detected in 64 of 65 (98.5%)
PV sera, in 34 (52.3%) of these sera, additional anti-Dsg1
reactivity was found. Staining of a representative PV
serum is shown in Figure 1C. Anti-Dsg1 reactivity was
present in 45 of 50 (90%) PF sera. Specificities for indir-
ect IF microscopy on monkey esophagus, anti-Dsg1 re-
activity, and anti-Dsg3 reactivity were 89.1%, 100%, and
99.6%, respectively (Table 3).
Correlation of serum autoantibody levels with disease
activity
Sera of nine patients (BP, n = 3; PF, n = 3; PV, n = 3) taken
during the course of the disease were analyzed by boththe BIOCHIP mosaic and conventional ELISA. IF titers
by the novel biochip paralleled both ELISA values and
disease activity (Figure 2).Prospective study on the diagnostic agreement between
the BIOCHIP mosaic and the conventional multi-step
procedure
When the 454 consecutive sera from patients with sus-
pected autoimmune blistering disease were subjected to
both indirect IF with the BIOCHIP mosaic and the con-
ventional multi-step procedure, concordant diagnoses
were obtained in 425 (93.6%) of sera (κ value of 0.88)
(Figure 3). BP was diagnosed in 17.8% (n = 81), PV in
3.1% (n = 14), and PF in 1.1% (n= 5). In 322 sera (70.9%),
Figure 2 Correlation of serum autoantibody levels with disease activity. Values by conventional ELISA (Dsg3 (A), Dsg1 (C), BP180 (E))
paralleled indirect immunofluorescence titers by the BIOCHIP mosaic (Dsg3 (B), Dsg1 (D), BP180 (E)) obtained by testing sera from patients with
pemphigus vulgaris (PV1-3) (A,B), pemphigus foliaceus (PF1-3) (C,D), and bullous pemphigoid (BP1-3) (E,F). Both ELISA values and indirect
immunofluorescence titers appeared to correlate with disease activity determined by a clinical score (4, more than 10 lesions; 3, 4–10 lesions; 2,
1–3 lesions; 1, clinical remission on immunosuppressive therapy; 0 clinical remission without immunosuppressive therapy). Dsg, desmoglein; IF,
immunofluorescence.
Figure 3 Evaluation of the BIOCHIP mosaic for the routine diagnosis of autoimmune bullous diseases. A large panel of consecutive sera
(n = 453) from patients with suspected autoimmune bullous disease was subjected to both the BIOCHIP mosaic (black columns) and the routine
multi-step procedures of the autoimmune laboratory of the department of dermatology, Luebeck (grey columns; detailed in [38]). Obtained
diagnoses were grouped into BP (bullous pemphigoid), “pemphigoid” diseases (including linear IgA disease, p200-pemphigoid, mucous
membrane pemphigoid and dermatitis herpetiformis), PV/PNP (pemphigus vulgaris/ paraneoplastic pemphigus), PF (pemphigus foliaceus), and
PG (pemphigoid gestationis). PNP and “pemphigoid” sera are further specified in Table 4.
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for the diagnosis of BP, PV, PF, and negative sera was
found reflected by κ values of 0.97, 0.91 and 0.88, respect-
ively (Figure 3). In 3 sera, both approaches resulted in the
diagnosis of pemphigoid gestationis.
In a small portion of sera (n = 21; 4.6%), the conven-
tional multi-step procedure identified additional disor-
ders, including mucous membrane pemphigoid (MMP)
(n = 6), linear IgA disease (n = 6), anti-p200 pemphigoid
(n = 5), dermatitis herpetiformis (n = 2), and paraneoplas-
tic pemphigus (n = 2). Four of these 21 sera, 2 with
MMP, 1 with anti-p200 pemphigoid, and 1 with linear
IgA disease, were diagnosed as “pemphigoid” by the
BIOCHIP technique based on detection of autoanti-
bodies against BP180 and positive staining on esophagus
and/or salt-split skin (Figure 3). The exact results
obtained with these sera are detailed in Table 4. After
these primary analyses, incongruent results between the
conventional multi-step procedure and the BIOCHIP
mosaic, which were not explained by the different com-
position of the two approaches, were seen in 8 (1.8%)
sera. For these 8 sera, tests were repeated and appropri-
ate additional analyses were performed, including MBL
ELISAs. This post-hoc analysis resolved 5 discrepant
results leaving incongruent analyses in 3 (0.7%) sera
(Table 4).
Discussion
The identification of target antigens in the great majority
of autoimmune bullous diseases has led to the devel-
opment of standardized specific and sensitive diagnos-
tic assays, some of them have been commercialized
[17,19-23,30,32,34-37,41-45] (Table 1). By the use of theseTable 4 Incongruent results obtained by the BIOCHIP mosaic
Conventional procedure Bio
Diagnose Findings Dia
LAD, n = 6 2 with linear IgA deposits on salt-split skin,
4 with anti-LAD-1 IgA reactivity
NS
p200, n = 5 linear IgG deposits on salt-split skin and
anti-p200 protein/ laminin γ1 reactivity
NS
MMP, n = 6 3 with anti-LAD-1 IgG reactivity, 3 with
anti-laminin 332 reactivity
NS
DH, n = 2 IgA reactivity with endomysium on monkey
esophagus and anti-transglutaminase IgA reactivity
NS
PNP, n = 2 Both with anti- Dsg3 reactivity and anti
envoplakin reactivity
PV
BP, n = 2 positive BP180NC16A ELISA NS
NS, n = 1 No IR PV
In 21 sera (white background), final diagnosis was based on findings by convention
could be made. In these cases, direct immunofluorescence microscopy would be re
IR, immunoreactivity; LAD, linear IgA dermatosis; LAD-1, linear IgA dermatosis antig
membrane pemphigoid; DH, dermatitis herpetiformis; BP, bullous pemphigoid; PV,
desmoglein 3.assays, exact diagnosis can be made, which is of both
prognostic and therapeutic relevance. Disease’s prognosis
may be greatly unfavorable in patients with paraneo-
plastic pemphigus [46] and anti-laminin-332 mucous
membrane pemphigoid [47]. In addition, treatment of
epidermolysis bullosa acquisita and pemphigus vulgaris
is frequently challenging, while in linear IgA disease,
anti-p200 pemphigoid, and in many patients with BP,
complete remission can usually be achieved with rela-
tively mild immunosuppression [48-50]. Target-specific
diagnostic assays are usually applied in a multi-step ap-
proach, starting with a screening test for anti-desmosomal
and anti-basal membrane zone antibodies using indirect
IF microscopy on monkey esophagus and salt-split skin
[15,24-26,38].
In the present study, a BIOCHIP mosaic was com-
posed allowing the simultaneous detection of autoanti-
bodies against the most frequent target antigens to
facilitate the diagnosis of bullous skin diseases. Six dif-
ferent substrates were included: monkey esophagus, pri-
mate salt-split skin, recombinant BP180 NC16A-4X
(antigen dots) and membrane-bound Dsg1 ectodomain,
Dsg3 ectodomain, and the C-terminal globular domain
of BP230. Additional substrates such as transitional epi-
thelium and cells expressing the immunodominant por-
tions of laminin 332, α6β4 integrin, and type VII
collagen that would possibly have improved the detec-
tion of autoantibodies in paraneoplastic pemphigus
(PNP), MMP, and epidermolysis bullosa acquisita, re-
spectively, were not included due to the rarity of these
disorders.
Validation of the BIOCHIP mosaic with sera from BP,
PV, and PF patients revealed high sensitivities andand the conventional procedure
chip mosaic
gnose Findings
, n = 5; pemphigoid, n = 1 1 with linear IgG/IgA deposits on salt-split
skin; 5 without IR
, n = 3; pemphigoid, n = 2 2 with linear IgG/IgA deposits on monkey
esophagus and salt split skin; 3 without IR
, n = 4; pemphigoid, n = 2 2 with linear IgG/IgA deposits on monkey
esophagus and salt-split skin; 4 without IR
, n = 2 no IR
, n = 2 intercellular IgG/IgA deposits on monkey
esophagus and Dsg 3-transfected cells
, n = 2 no IR
, n = 1 intercellular IgG/IgA deposits on monkey
esophagus and Dsg 3-transfected cells
al procedures as explained. In 3 sera (grey background), no final diagnosis
quired.
en 1(soluble ectodomain of BP180); p200, p200-pemphigoid; MMP, mucous
pemphigus vulgaris; NS, normal serum; PNP, paraneoplastic pemphigus; Dsg 3,
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tional approaches e.g. Dsg3 Elisa (97.5-100% and 95.8-
97.9%), Dsg1 Elisa (96.0-97.9% and 95.8-97.9%) BP1
80NC16A Elisa (84.4-89.9% and 97.8-98.9%), and BP230
Elisa (63.0-72.4% and 93–99.5%) [17,19,20,22,30,51,52]
(Tables 2 and 3). Previously, indirect IF microscopy of
Sf21 insect cells expressing full-length BP180 has shown
a sensitivity and specificity of 89% and 100%, respec-
tively, when probed with BP and control sera [53], how-
ever, this test is not widely available. The use of HEK293
cells results in the exclusive expression of the mature
Dsg1 and Dsg3 forms, which have previously been shown
to harbor major pathogenic epitopes on these two ecto-
domains [54,55]. Cells transfected with the corresponding
“empty” plasmid serve as negative control substrates.
To explore the practical application of the BIOCHIP
mosaic in the setting of a diagnostic routine laboratory,
454 consecutive sera from patients with suspected auto-
immune blistering disease were probed independently
using the novel BIOCHIP mosaic IF assay and the rou-
tine multi-step diagnostic approach. Results were com-
pared only after the two sets of experiments were
completed. High concordance with κ values between
0.88 and 0.97 was observed for the diagnoses of BP, PV,
PF, and “negative”.
As expected, the BIOCHIP mosaic did not exactly
identify all entities. In fact, in only a small portion of
sera (3.7%), the BIOCHIP mosaic was unreactive, while
the conventional multistep procedure revealed an auto-
immune bullous disease, and in 0.9% of sera, pemphig-
oid diseases other than BP were detected. The reasons
for this comprise the use of an anti-IgA/IgG secondary
antibody and the lack of additional target antigens in the
BIOCHIP mosaic. The anti-IgA/IgG secondary antibody
allows the simultaneous detection of IgG and IgA anti-
bodies which is practical and increases the sensitivity as
most sera from patients with BP and MMP [33,56,57])
and many sera from patients with EBA contain IgA
autoantibodies in addition to IgG reactivity [58]. How-
ever, this secondary antibody does not allow the diagno-
sis of linear IgA disease and dermatitis herpetiformis.
For the diagnosis of anti-laminin 332 mucous membrane
pemphigoid, anti-p200/ laminin γ1 pemphigoid, epider-
molysis bullosa acquisita, and paraneoplastic pemphigus
additional target antigens need to be included in the
BIOCHIP mosaic. The complementation of the BIO-
CHIP mosaic, which may be extended to up to 16 BIO-
CHIPs in one incubation field, with additional target
antigens will, however, only be helpful in a small portion
of sera (<5%). In fact, meanwhile, an IF microscopy-
based assay employing the membrane-bound immuno-
dominant NC1 domain of type VII collagen expressed in
HEK293 cells has been shown as a highly sensitive and
specific tool for the serological diagnosis of epidermolysisbullosa acquisita [36]. For the routine application of the
current BIOCHIP mosaic we recommend the diagnostic
pathway detailed in Additional file 1: Figure S1.
After the initial analysis, discordant results, which
were not explained by the different composition of the
BIOCHIP mosaic and the multi-step procedure, were
seen in only 8 (1.8%) sera. Following post hoc analysis,
inconclusive results remained in 3 (0.7%) sera. Since
sera had been anonymized, direct IF microscopy could
not be performed to clarify the discrepant results in
these 3 sera.
It has previously been shown that the investigation of
anti-BP230 reactivity in addition to BP180-specific anti-
bodies is only of little diagnostic relevance [59-61]. Since
all sera in our relatively small cohort of 42 BP patients
contained anti-BP180 antibodies, the diagnostic value of
the BP230gC BIOCHIP containing the entire globular
C-terminal domain of BP230 could not be assessed. In
BP, PV, and PF, autoantibody serum levels were shown
to correlate with disease activity [18,62]. Monitoring of
serum autoantibody levels during the course of disease
may therefore be helpful in the treatment of patients.
For the monitoring of autoantibody levels, the available
ELISA kits appear to be more convenient than the novel
BIOCHIP mosaic.
Conclusions
BIOCHIP mosaic-based indirect IF technique is useful
in screening autoantibodies for routine diagnosis of BP,
PV, and PF. Results are concordant compared with the
routine multi-step diagnostic procedure. This simple,
standardized, and readily available novel tool will further
facilitate the diagnosis of autoimmune bullous diseases.
Additional file
Additional file 1: Figure S1. Proposed diagnostic pathway following
analysis by the BIOCHIP mosaic. LAD-1, linear IgA dermatosis antigen 1
(soluble ectodomain of BP180).
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